Bellevue Group’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-266,226
| Closed | -$34.5M | – | 170 |
|
|
2023
Q3 | $34.5M | Sell |
266,226
-22,553
| -8% | -$3.01M | 0.56% | 50 |
|
|
2023
Q2 | $35.8M | Sell |
288,779
-281,078
| -49% | -$37.8M | 0.51% | 61 |
|
|
2023
Q1 | $83.4M | Sell |
569,857
-186,779
| -25% | -$27.6M | 1.21% | 26 |
|
|
2022
Q4 | $121M | Sell |
756,636
-67,203
| -8% | -$9.85M | 1.6% | 13 |
|
|
2022
Q3 | $110M | Sell |
823,839
-94,068
| -10% | -$14.3M | 1.58% | 16 |
|
|
2022
Q2 | $143M | Buy |
917,907
+162,926
| +22% | +$25.1M | 2.02% | 13 |
|
|
2022
Q1 | $118M | Sell |
754,981
-131,873
| -15% | -$19.1M | 1.36% | 21 |
|
|
2021
Q4 | $113M | Buy |
886,854
+117,616
| +15% | +$15.5M | 1.16% | 27 |
|
|
2021
Q3 | $100M | Buy |
769,238
+224,488
| +41% | +$33.9M | 1.02% | 32 |
|
|
2021
Q2 | $96.8M | Sell |
544,750
-5,900
| -1% | -$1.02M | 0.94% | 33 |
|
|
2021
Q1 | $90.5M | Buy |
550,650
+161,785
| +42% | +$26.6M | 0.96% | 33 |
|
|
2020
Q4 | $64.2M | Buy |
388,865
+32,515
| +9% | +$4.84M | 0.74% | 40 |
|
|
2020
Q3 | $50.8M | Buy |
356,350
+65,214
| +22% | +$8.08M | 0.7% | 42 |
|
|
2020
Q2 | $32.1M | Sell |
291,136
-80,201
| -22% | -$8.87M | 0.45% | 56 |
|
|
2020
Q1 | $37M | Sell |
371,337
-9,966
| -3% | -$1.29M | 0.72% | 38 |
|
|
2019
Q4 | $56.9M | Buy |
381,303
+51,076
| +15% | +$6.95M | 0.9% | 34 |
|
|
2019
Q3 | $42.3M | Sell |
330,227
-1,946
| -0.6% | -$261K | 0.79% | 37 |
|
|
2019
Q2 | $47.4M | Buy |
332,173
+64,735
| +24% | +$8.7M | 0.81% | 36 |
|
|
2019
Q1 | $38.2M | Buy |
267,438
+6,790
| +3% | +$886K | 2.1% | 11 |
|
|
2018
Q4 | $32.3M | Buy |
260,648
+46,890
| +22% | +$6.96M | 2.12% | 13 |
|
|
2018
Q3 | $35.9M | Buy |
213,758
+48,825
| +30% | +$8.4M | 2.28% | 11 |
|
|
2018
Q2 | $28.4M | Buy |
164,933
+13,211
| +9% | +$2.16M | 2.42% | 10 |
|
|
2018
Q1 | $22.9M | Sell |
151,722
-3,860
| -2% | -$566K | 2.27% | 11 |
|
|
2017
Q4 | $20.9M | Buy |
155,582
+40,330
| +35% | +$5.59M | 2.19% | 11 |
|
|
2017
Q3 | $16.9M | Buy |
115,252
+15,049
| +15% | +$2.28M | 1.76% | 17 |
|
|
2017
Q2 | $15.6M | Sell |
100,203
-6,397
| -6% | -$978K | 1.84% | 14 |
|
|
2017
Q1 | $15.5M | Buy |
106,600
+22,800
| +27% | +$2.97M | 2.06% | 14 |
|
|
2016
Q4 | $9.14M | Hold |
83,800
| – | – | 1.87% | 17 |
|
|
2016
Q3 | $10.2M | Buy |
83,800
+8,500
| +11% | +$1.15M | 1.84% | 15 |
|
|
2016
Q2 | $10.6M | Buy |
75,300
+12,800
| +20% | +$1.89M | 2% | 13 |
|
|
2016
Q1 | $8.16M | Buy |
+62,500
| New | +$7.78M | 1.48% | 19 |
|
Other funds holding JAZZ
PCM
Bellevue Group's JAZZ Position: Q4 2023 in Review
Bellevue Group sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 266,226 shares — an estimated $34.5M sold.
Bellevue Group first reported a position in JAZZ in Q1 2016 and held it in 31 quarters. The position peaked at $143M in Q2 2022. 499 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.
- Bellevue Group reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Bellevue Group sold 266,226 Jazz Pharmaceuticals shares in Q4 2023, an estimated $34.5M.
- Bellevue Group first reported a position in Jazz Pharmaceuticals in Q1 2016 and held it in 31 quarters.
- Bellevue Group's Jazz Pharmaceuticals position peaked at $143M in Q2 2022.
- 499 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.
Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.